impact of depot medroxyprogesterone (dmpa) on human vaginal leukocytes and hiv-1 target cells andrea...
TRANSCRIPT
![Page 1: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/1.jpg)
Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes
and HIV-1 Target Cells
Andrea Ries Thurman MDNeelima Chandra PhD
(PI) Gustavo F Doncel MD PhD
23 JULY 2012
![Page 2: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/2.jpg)
Background
• Depot Medroxyprogesterone Acetate (DMPA):– Highly effective long acting reversible
contraceptive• Prevents Unintended/Mistimed Pregnancies
– Only one absolute contraindication– High usage in developing world• World Contraceptive Use 2009, UN Population Division
– Sole P-only injectable in the US
![Page 3: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/3.jpg)
Relevance: DMPA and HIV Acquisition
• Observational studies AOR 1.73 – 3.90 for increased HIV acquisition with DMPA use
• Ungchusak K et al. J AIDS Hum Retrovirol 1996• Martin HL et al. J Infect Dis 1998• Baeten JM et al. AIDS 2007• Morrison CS et al. AIDS 2010
• Sero-discordant couples: Injectable use ↑↑ HIV-1 acquisition and transmission (AHR 2 – 3)
• Heffron et al. Lancet Infect Dis 2012
• 2012 WHO meeting re-consider medical eligibility criteria for DMPA in women at high risk of HIV-1
• Category 1*
![Page 4: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/4.jpg)
Epithelial Thinning• Cell layers, height in µm– Dramatic Atrophy with P/DMPA in NHP models
• Marx PA et al. Nat Med 1996• Smith SM et al. J InfectDis 2000• Jiang Y et al. J Med Primatol 2009• Pal R et al. Virology 2009• Salle B et al. J Infect Dis 2010• Veazey RS et al. Nat Med 2003
– Humans• Bahamondes L et al. Contraception 2000• Mauck CK et al. Contraception 1999• Miller L et al. ObstetGynecol 2000• Ildgruben AK et al. ObstetGynecol 2003
![Page 5: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/5.jpg)
Epithelial Integrity
• Other markers of epithelial integrity• E Cadherin and Zona Occludin 1 (ZO-1)• Epithelial Cell Proliferation (Ki67)• E Cadherin density altered by vaginal estrogen
therapy• Gorodeski GI. Endocrinology 2007
![Page 6: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/6.jpg)
Alteration of MucosalImmune Cells
• Small cohorts support exogenous progesterone alters mucosal environment
– Wieser F et al. Fertil Steril 2001– Ildgruben AK et al. Obstet Gynecol 2003
• Most data on endogenous and exogenous hormones and alteration of mucosal inflammatory/immune cell populations in humans from endometrium
– Pudney et al. Biol Reprod 2005– Wira et al Am J Reprod Immunol 2011
![Page 7: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/7.jpg)
Objective
• Determine if exogenous and endogenous progesterone alters epithelial integrity and the cellular inflammatory status of the vaginal mucosa
• Secondary analysis– Mauck CK et al. Contraception 1999 Jul;60(1):15-24.
![Page 8: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/8.jpg)
Methods15 women (BTL, no hormonal contraception)
Luteal PhaseDays 22 - 26(Confirmed Serum P)
Follicular PhaseDays 8 - 12(Serum E2 and P)
12 weeks ± 1 week post DMPA
![Page 9: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/9.jpg)
Endpoints• Epithelial integrity– Epithelial height in µm (reticles) and # cell layers– Epithelial proliferation (Ki67 cells)– Intracellular adhesion proteins E Cadherin and ZO-1
(Integrated Optical Density - IOD)
• Immune cell populations by IHC– CD45, CD3, CD4, CD8, CD1a, CD68 bearing leukocytes– HLA-DR, CCR5 (markers of activation and proliferation )
![Page 10: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/10.jpg)
Results
• Demographic data (N = 15)– Mean age 35.9 (± 3.1) years-old– Mean weight 158.5 (± 25.0) pounds– Mean menstrual cycle length 29.0 (± 1.4) days– All with previous pregnancy– Mean gravidity 2.7 (± 1.1)
• Follicular versus luteal phase– All endpoints NS
![Page 11: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/11.jpg)
Epithelial Thickness& Proliferation
Epithelial characteristics
Mean ± standard deviation Median (25th, 75th quantile)
Paired T test P valueWilcoxan Signed Rank P Value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
Thickness (µm) 307.8 ± 96.8 269.6 ± 80.1 272.3 ± 94.6 0.33 0.94
# Cell layers 31.2 ± 8.1 28.2 ± 7.2 28.9 ± 6.5 0.42 0.79
Ki-67 35.7 (19.3, 64.3)
17.1 (9.0, 68.4)
72.6 (43.2, 126.9)
0.004 0.005
![Page 12: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/12.jpg)
Intracellular Adhesion Proteins (NS)
Epithelial adhesion proteins
Median integrated optical density (IOD)per stained field (X 106)
(25th, 75th percentile, quantile)*
Wilcoxon signedrank P value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
E Cadherin 3.5(0.4, 4.7)
1.6 (0.7, 8.1)
1.6(1.0, 3.2)
0.64 0.42
ZO-1 0.1 (0.03, 0.93)
0.2 (0.04, 0.65)
0.2 (0.04, 0.3)
0.38 0.22
![Page 13: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/13.jpg)
Luteal DMPA
ZO-1
E Cadherin
Follicular
![Page 14: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/14.jpg)
Immune Cells(Significant Increase with DMPA)
Phenotype vaginal
epithelial immune cells
Median cell count (cells/mm2) Wilcoxon signed rank P value
Follicular Phase
Luteal Phase DMPA Treatment
Follicular vs DMPA
Luteal vs DMPA
CD45 70.6 73.5 156.9 0.03 0.22
CD3 40.0 45.9 76.5 0.08 0.04
CD8 28.1 29.1 52.6 0.15 0.01
CD1a 26.4 27.6 33.9 0.13 1.00
CD68 1.5 3.3 7.2 0.01 0.07
![Page 15: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/15.jpg)
Activated Immune Cells (Significant Increase with DMPA)
Phenotype of Immune Cells in the Vaginal
Epithelium
Median Cell Count (cells/mm2)(25th, 75th percentile, quantile)
Wilcoxon Signed Rank P value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
CCR5 (LP) 0.2 (0, 0.5) 0.2 (0, 0.6) 0.8 (0, 1.2) 0.09 0.05
HLA-DR 97.4(81.0, 120.0)
82.4 (46.5, 102.6)
113.9 (85.1, 184.3)
0.02 0.35
![Page 16: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/16.jpg)
Follicular Luteal DMPA
H I
CD3
CD8
CCR5
HLA-DR
![Page 17: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/17.jpg)
CONCLUSIONS
• Epithelial Thinning (thickness, #cell layers) NS
• Epithelial Integrity (E Cadherin, ZO-1, Ki67) NS
• DMPA use resulted in significant increase in:–CD45, CD3, CD8, CD68 leukocytes–CCR5 (LP), HLA-DR, markers
![Page 18: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/18.jpg)
AcknowledgmentsCONRAD Microbicide Development Laboratory
Gustavo F Doncel MD PhD (Principal Investigator)Neelima Chandra PhDSharon Anderson PhDNazita Yousefieh PhD
Nancy GonyeaDept of Biostatistics Eastern Virginia Medical School
Tina D Cunningham PhD
CONRAD Clinical TeamChristine Mauck MD MPH
![Page 19: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/19.jpg)
Epithelial Thickness& Proliferation
Epithelial characteristics
Mean ± standard deviation Median (25th, 75th quantile)
Paired T test P valueWilcoxan Signed Rank P Value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
Thickness (µm) 307.8 ± 96.8 269.6 ± 80.1 272.3 ± 94.6 0.33 0.94
# Cell layers 31.2 ± 8.1 28.2 ± 7.2 28.9 ± 6.5 0.42 0.79
Ki-67+ 35.7 (19.3, 64.3)
17.1 (9.0, 68.4)
72.6 (43.2, 126.9)
0.004 0.005
![Page 20: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/20.jpg)
Intracellular Adhesion Proteins (NS)
Epithelial adhesion proteins
Median integrated optical density (IOD)per stained field (X 106)
(25th, 75th percentile, quantile)*
Wilcoxon signedrank P value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
E Cadherin 3.5(0.4, 4.7)
1.6 (0.7, 8.1)
1.6(1.0, 3.2)
0.64 0.42
ZO-1 0.1 (0.03, 0.93)
0.2 (0.04, 0.65)
0.2 (0.04, 0.3)
0.38 0.22
![Page 21: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/21.jpg)
Luteal DMPA
ZO-1
E Cadherin
Follicular
![Page 22: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/22.jpg)
Immune Cells(Significant Increase with DMPA)
Phenotype vaginal
epithelial immune cells
Median cell count (cells/mm2) Wilcoxon signed rank P value
Follicular Phase Luteal Phase DMPA Treatment
Follicular vs DMPA
Luteal vs DMPA
CD45 70.6 (37.5, 159.6)
73.5 (31.7, 120.3)
156.9 (112.4, 277.3)
0.03 0.22
CD3 40.0 (23.8, 60.0)
45.9 (11.3, 70.7)
76.5 (47.8, 117.9)
0.08 0.04
CD4 (LP) 0 (0, 0) 0 (max 11.6) 0 (max 9.3) NA NA
CD8 28.1 (18.4, 44.9)
29.1 (9.3, 54.4)
52.6 (40.9, 85.6)
0.15 0.01
CD1a 26.4 (16.7, 60.9)
27.6 (17.8, 41.7)
33.9 (26.0, 54.9)
0.13 1.00
CD68 1.5 (0, 5.1) 3.3 (0, 5.4) 7.2 (3.9, 22.0) 0.01 0.07
![Page 23: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/23.jpg)
Activated Immune Cells (Significant Increase with DMPA)
Phenotype of Immune Cells in the Vaginal
Epithelium
Median Cell Count (cells/mm2)(25th, 75th percentile, quantile)
Wilcoxon Signed Rank P value
Follicular Luteal DMPA Follicular vs DMPA
Luteal vs DMPA
CCR5 (LP) 0.2 (0, 0.5) 0.2 (0, 0.6) 0.8 (0, 1.2) 0.09 0.05
HLA-DR 97.4(81.0, 120.0)
82.4 (46.5, 102.6)
113.9 (85.1, 184.3)
0.02 0.35
![Page 24: Impact of Depot Medroxyprogesterone (DMPA) on Human Vaginal Leukocytes and HIV-1 Target Cells Andrea Ries Thurman MD Neelima Chandra PhD (PI) Gustavo F](https://reader030.vdocuments.mx/reader030/viewer/2022032803/56649e2c5503460f94b1ade1/html5/thumbnails/24.jpg)
Follicular Luteal DMPA
H I
CD3
CD8
CCR5
HLA-DR